Elizabeth A. Eisenhauer

Author

Also Known As

E A Eisenhauer, E Eisenhauer, E. A. Eisenhauer, E. EISENHAUER, E. Eisenhauer, E.A. EISENHAUER, E.A. Eisenhauer, ELIZABETH A. EISENHAUER, ELIZABETH EISENHAUER, Eisenhauer, Elizabeth

269

Publications

61.9K

Citations

H-Index

Concepts

All Affiliations

Queen's University Princess Margaret Cancer Centre BC Cancer Agency Ontario Institute for Cancer Research Ottawa Regional Cancer Foundation

About

Elizabeth A. Eisenhauer is an author at Queen's University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	72	29.2K
2	Health Sciences	14	15	17.7K
3	Public Health	3	3	264
4	Engineering	2	2	149
5	Nursing	1	1	48

Elizabeth A. Eisenhauer

138

Publications

58.7K

Citations

H-Index

Page 1

	Year	Citations
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma Roger Stupp, Warren Mason, Martin J. van den Bent, New England Journal of Medicine	2005	21K
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Roger Stupp, Monika E. Hegi, Warren Mason, The Lancet Oncology 5-Year AnalysisNeuro-oncologyOncologyRadiation TherapyAdjuvant Temozolomide	2009	7.7K
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG Jacobus Pfisterer, Marie Plante, Ignace Vergote, Journal of Clinical Oncology	2006	746
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials Edward L. Korn, Ping-Yu Liu, Sandra J. Lee, Journal of Clinical Oncology	2008	695
New guidelines to evaluate the response to treatment in solid tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Breast Cancer Solid TumorsMedicineCancer ManagementNew GuidelinesCancer Treatment	2005	662
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Elizabeth A. Eisenhauer, W.W. ten Bokkel Huinink, Kenneth D. Swenerton, Journal of Clinical Oncology	1994	640
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) Gordon John Sampson Rustin, Ignace Vergote, Elizabeth A. Eisenhauer, International Journal of Gynecological Cancer	2011	600
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 Thierry Gorlia, Martin J. van den Bent, Monika E. Hegi, The Lancet Oncology Neuro-oncologyPrognostic BiomarkersGliomaNcic TrialPrognostic Factor Analysis	2007	543
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group Amit M. Oza, Laurie Elit, Ming‐Sound Tsao, Journal of Clinical Oncology	2011	333

Page 1